Idioma:

Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions

Koutsky, LA

The New England journal of medicine, 2007-05, Vol.356 (19), p.1915-1927 [Periódico revisado por pares]

Boston, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
Autor: Koutsky, LA
Assuntos: Adenocarcinoma - epidemiology ; Adenocarcinoma - prevention & control ; Adolescent ; Adult ; Alphapapillomavirus ; Basic Medicine ; Biological and medical sciences ; Cervical cancer ; Cervical Intraepithelial Neoplasia - epidemiology ; Cervical Intraepithelial Neoplasia - prevention & control ; Clinical outcomes ; Clinical trials ; Disease prevention ; DNA, Viral - blood ; Double-Blind Method ; Female ; Follow-Up Studies ; General aspects ; Human papillomavirus ; Human papillomavirus 16 - genetics ; Human papillomavirus 16 - isolation & purification ; Human papillomavirus 18 - genetics ; Human papillomavirus 18 - isolation & purification ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ; Humans ; Medical and Health Sciences ; Medical sciences ; Medicin och hälsovetenskap ; Medicinska och farmaceutiska grundvetenskaper ; Microbiology in the medical area ; Mikrobiologi inom det medicinska området ; Papillomavirus Infections - prevention & control ; Papillomavirus Vaccines - adverse effects ; Prevention ; Prevention and actions ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Time Factors ; Treatment Outcome ; Uterine Cervical Neoplasms - epidemiology ; Uterine Cervical Neoplasms - prevention & control
É parte de: The New England journal of medicine, 2007-05, Vol.356 (19), p.1915-1927
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-News-2
ObjectType-Feature-3
Descrição: In this large, randomized, placebo-controlled trial, a quadrivalent vaccine (including human papillomavirus types 6, 11, 16 and 18) given at day 1, month 2, and month 6 was associated with a significant reduction in the occurrence of cervical intraepithelial neoplasia. No beneficial effect was observed on prevalent lesions. The prevention benefit for incident lesions associated with HPV-16 and HPV-18 appears to increase with time. A quadrivalent vaccine (including human papillomavirus types 6, 11, 16 and 18) was associated with a significant reduction in the occurrence of cervical intraepithelial neoplasia. The prevention benefit for incident lesions associated with HPV-16 and HPV-18 appears to increase with time. Cervical cancer is the second most common cancer in women and the leading cause of cancer-related death in many developing countries. 1 Although well-organized programs for Papanicolaou screening have led to a significant decline in mortality from cervical cancer in developed countries, 1 such programs are costly 2 and have not been effectively implemented in most developing countries. 3 Human papillomaviruses (HPVs) cause virtually all cervical cancers, with HPV types 16 (HPV-16) and 18 (HPV-18) responsible for approximately 70%. 4 When phase 3 trials of prophylactic HPV vaccines were in the planning stages, the vaccine advisory committee of the Food and Drug Administration (FDA) recommended . . .
Editor: Boston, MA: Massachusetts Medical Society
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 4 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions

Koutsky, LA

Boston, MA: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.